about
Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression.Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis.Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18.Role of active drug transporters in refractory multiple myeloma.The immune escape in melanoma: role of the impaired dendritic cell function.Avβ3 integrin: Pathogenetic role in osteotropic tumors.Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications.miRNAs in melanoma: a defined role in tumor progression and metastasis.An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation.A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progressionPTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression.In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.Nef protein induces differential effects in CD8+ cells from HIV-1-infected patients.beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells.Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma.Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and alpha-interferon therapy.Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker.Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis.Does cilengitide deserve another chance?Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation.Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma.Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer.Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia.Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanomaEnhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupusUpregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone diseaseFunctional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopeniaUrinary biomarkers in lupus nephritisInterleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathiesGlomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritisOverexpression of interleukin-12 and T helper 1 predominance in lupus nephritisGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
P50
Q32061748-408FC4EB-BD3E-4FF4-8D36-530E62BD77FFQ34109952-06C32DCB-8086-406A-83E7-7E93E51E999EQ35584599-8C6CC517-C008-46C9-A831-E5F687755F3FQ35807838-188AEB69-2268-4D25-ACC1-B930852D41B5Q35921190-29D6331E-368D-4D21-ABC5-42149A394676Q36242845-D6DD5630-A86D-4D05-AD5B-4CA100F78CBBQ36281248-FFCFC752-C19A-4275-A311-6D0F7612EB7DQ37387629-04CA9FA1-6045-4E8E-94CF-9CD1E7702143Q38250071-F31A92C4-DEA9-4D53-9072-3488C5A193A4Q38540840-05339806-13B6-4D0C-8CCB-31BFCA2FC4F4Q38593774-1FEF88C2-0CEB-4905-AD4E-57DA92CF47CDQ38617229-E9A12D05-8B09-439A-807B-9D0919B24B66Q38980447-7060739A-C8D8-45E2-B855-646473976423Q39030703-F24CBA7D-C065-42C3-8EA4-54C6F906CAACQ39137073-68CFB30B-8984-479B-8021-10D0376EB865Q39379196-4529DABF-F421-40B2-9D8E-FE08D9CD16C0Q40147550-0F251012-C2D6-4951-8AB0-960A9FF04D0EQ42808088-4A15554D-BF2B-47EB-9EB6-BE630B1A3C8CQ43298697-8202086B-9882-461A-8B9A-C5966D5603E7Q43878419-63A5E699-23AC-47D3-A767-D1229C9AD147Q44940546-C89A7DA9-772F-49D0-9009-F888B4E32D74Q45752130-79C7B98C-C415-4418-8299-365508980DB7Q47368439-9D6E050F-F32F-42A8-BAD0-E953E31E2612Q48431517-18543529-DE08-4899-AF60-A9F068DA1AF7Q51063770-BD850E54-70B7-4BD6-9892-2B52028E7A9EQ51372185-186C23C5-1742-4C27-9793-8082F399552EQ53073457-E6DF34D0-F8B7-40D5-BEBD-57EDEAE4B5DEQ54373221-6CC60731-7208-4317-9169-056A2E6E92F1Q54595536-C0A2B34A-B5CF-4C37-9874-38BDD89504DFQ59403918-C89F43E7-F99D-4825-92A4-AB5C842B9765Q62071797-484078A5-CE64-4FEF-B21A-D8A7F6F2600DQ62071798-0C4ADC6B-6A22-4B0F-8088-CF0AF95A142DQ62071807-AAAEEBCA-C81F-46D4-B242-45BE7838BFD9Q80064159-6879EA59-F6C6-4ABA-AC39-4EBB8C86A3D0Q80249710-AAF975FB-10EA-4E9E-A3AD-083D996E1FD2Q80419619-34A33957-E71B-4199-B2CC-E2381039D1A7Q80576943-5C54360A-6A5E-403A-BE73-DF8ABB530E0CQ81973156-CED8757E-ED3A-4C5E-B0DC-2CB31D800AAFQ87139132-FA053818-1E7E-4729-9B85-8E2B56FCEB3AQ90446250-6D3E956D-4C59-43E2-BFFD-C1B95C492A62
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marco Tucci
@ast
Marco Tucci
@en
Marco Tucci
@es
Marco Tucci
@sl
type
label
Marco Tucci
@ast
Marco Tucci
@en
Marco Tucci
@es
Marco Tucci
@sl
prefLabel
Marco Tucci
@ast
Marco Tucci
@en
Marco Tucci
@es
Marco Tucci
@sl
P106
P1153
7103222776
P21
P31
P496
0000-0003-4008-4897